Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Summary

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Early Breast Cancer

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

18 to 100 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Novartis Pharmaceuticals

Last updated on ClinicalTrials.gov

October 14, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites